Canary Foundation

The goal of the Canary Scientific Programs is to develop blood tests and imaging tests that can together be used to detect lethal cancers at a curable stage. Our plan for early and accurate cancer detection involves first screening patients with a blood test and then moving those patients who tested positive to a high-resolution imaging test to further isolate cancer so that it can be removed. Canary Foundation is focused on five cancer types, each of which presents a significant opportunity to save lives and prevent unnecessary treatments through early detection of otherwise lethal disease: cancer of the ovary, pancreas, lung, breast and prostate. Chances of survival are highest when cancer is detected before it spreads. Thus, accurate detection of cancer that would otherwise be lethal at its earliest stage promises to dramatically improve survival after diagnosis. Canary supports early detection

Canary Lung Cancer Program:Canary is focused on developing diagnostics with high sensitivity and specificity to detect otherwise lethal lung cancers at a stage when they are readily curable. To this end, Canary has assembled a team of experts who are collaborating to discover and validate biomarkers for blood and imaging tests that together will identify individuals harboring lethal lung cancers so that they can be removed.The Canary Lung Cancer Program has supported the development and maintenance of critical biospecimen resources, blood biomarker discovery and validation, molecular imaging projects for early detection of lethal lung cancer, and epidemiology and modeling for effective lung cancer screening. (Continued on Schedule O)

research programs in each of these cancer areas as well as a Collaborations Program with collaborating early detection programs and centers that include the Canary Center at Stanford for Cancer Early Detection.Canary Ovarian Cancer Program: The goal of our ovarian research program is to develop a strategy to accurately identify ovarian cancers that would otherwise be lethal at a stage when they are readily curable. Our vision is of a two-stage screening strategy, consisting of a simple blood test followed by a molecular imaging test. Development of blood and imaging tests follows a similar roadmap; both include biomarker discovery followed by validation, but they also involve different techniques and challenges.